Submission mode: Abstract submission is only possible online. Abstracts submitted by post, fax or email will NOT be accepted. The online abstract submission module will NOT be available after 15 September 2024.

IDF congress  profile: In order to submit an abstract, a congress profile must be created giving access to the online abstract submission module. The submitting author must ensure accurate contact details are entered. One or more abstracts can be submitted by logging into this congress profile.

Submitting and presenting author: If the submitting author is not also the presenting author, the submitting author is responsible for informing the presenting author of all communications received regarding the abstract.

Presenting author registration: The presenting author must be registered by 31 December 2024. If the presenting author is not registered by this date their abstract will be REMOVED from the programme. To benefit from the early registration rate, the presenting author must register by 31 October 2024. After this date the standard rate will apply.

Number of submissions: There can only be ONE presenting author per abstract. The same abstract CANNOT be submitted multiple times by listing different presenting authors. An unlimited number of abstracts can be submitted by one author.

Language: All abstracts must be submitted  in English. Should English not be your first language, you may wish to have your abstract examined by a native English speaker prior to submission.

ENCORE abstracts/Originality of abstracts: Work published in peer-reviewed journals before 7 April 2025 CANNOT be submitted to the IDF World Diabetes Congress 2025. Abstracts already presented at face-to-face meetings can also NOT be submitted. However, previously submitted work can be resubmitted provided there are new methods and/or findings. Abstracts already presented at a national virtual meeting can be resubmitted. However, previously  submitted work CANNOT be resubmitted, if it was presented at an international virtual meeting.

Disclosure of interests: Any financial relationships with commercial entities related to the authors or products and processes described in the work must be correctly disclosed.

Regulatory approval: The submitting author confirms that local regulatory approval has been obtained as required by local laws.

Author consent: The submitting author declares all authors have read and approved the submitted work.

Copyright transfer: Authors must attest that their submitted work does not infringe any copyright legislation. Copyright for the publication of abstracts is automatically transferred to the International Diabetes Federation upon submission and acceptance of the regulations within the online submission module. For rejected abstracts, the copyright reverts back to the authors.

Publication in DRCP: Best abstracts will be published online in the IDF official journal Diabetes Research and Clinical Practice (DRCP). The approximate publication date is Sep/Oct 2025. Accepted abstracts will be published as submitted through the IDF 2025 Abstract Submission Portal. Any changes made to the digital poster submission will not be reflected in DRCP. Abstracts cannot be removed or corrected once they are published in DRCP.

Topic: There are various categories that have been defined for the abstract programme within the ten streams. Ensure that you select the MOST relevant stream that BEST reflects the content of your abstract. Categories are used for reviewing and indexing purposes.

Abstract title: The title is limited to 120 characters including spaces and should be brief and relevant. Special characters can NOT be used in the title and should be spelt out instead (e.g. α needs to be written as alpha, β as beta). Only standard abbreviations and generic drug names are allowed  in the title.

Authors: Only 12 authors and/or study groups can be listed. Only one institution can be entered per author.

Abstract body:

• The abstract structure is laid out under the headings: Background, Aim, Method, Results, Conclusion and References.
• Font size and style will be automatically configured by the system.
• Tables Maximum of 1 Table OR 1 Figure will be accepted in the submission field and count towards the character limit. Figures or Tables included in an abstract need to have a mention of this in the abstract text (e.g. Table or Figure 1). The character deduction for tables is not fixed and will be generated by the character count shown below the submission field. The table/figure must not contain more than 480 characters. The table must have a maximum of 10 columns and 12 rows. Figures must have a maximum of two panels. Images and photographs are NOT allowed.
• The length of the abstract is limited to 2100 characters with spaces. Only the abstract body and any inserted tables count towards this character limit. The character count displayed beneath the submission field is final and indisputable.
• Only commonly accepted abbreviations should be used (e.g. GDM, BMI, DM). Treatment groups or drug names should NOT be abbreviated. Less widely recognised abbreviations may be used if introduced on first usage (e.g. ambulatory blood pressure monitoring, ABPM).
• Only approved and generic (non-proprietary) drug names should be used.
• Do NOT enter the title, authors, or grant information into the abstract body, but you can include up to three references at the end of the abstract. References need to be numbered (reference number in square brackets) and must have a matching citation number (citation number in square brackets).

Selection: All submitted abstracts will undergo review by the Programme Committee. Accepted abstracts are selected for oral presentation, poster presentation or e-poster gallery display. The Programme Committee reserves the right to accept or reject any submitted abstract and re-categorise any accepted abstract. The decision of the Programme Committee is final and irrevocable.

Notification: Notice of acceptance or rejection of submitted abstracts will be sent to the submitting authors by 25 October 2024. It is the responsibility of the submitting author to inform all other authors of the status of the abstract. A submitting author may also check their congress profile to see the status of their abstract.